

12 October 2016

US Patent and Trademark Office grants OBJ two new microarray patents

OBJ Limited (ASX: OBJ) is pleased to report that the United States Patent and Trademark Office (USPTO) has granted two new US patents pertaining to the OBJ magnetic microarray technology for use in Skincare and in Oral Healthcare.

The granting of patent rights in the USA for the use of magnetic microarrays in skincare and oral healthcare applications provides OBJ with the ability to offer patent protected market exclusivity in the world's largest market.

The patents granted by the USPTO have a life of 20 years from the earliest filing date of the applications. Prosecution of the same patent applications is continuing in Europe.

The granting of the patents will be welcomed by OBJ's partners, given the protection it potentially provides for products incorporating OBJ's magnetic microarray technology.

OBJ has similar patent filings covering the use of magnetic microarrays in surface hygiene and muscular-skeletal health.

"For our major partners, protection in the world's largest, single skincare market is very important from a strategic perspective," said Glyn Denison, OBJ's non-executive chairman.

"It provides our partners with the ability to create unique products that they can confidently invest in. The OBJ technology already provides significant benefits in product performance, and now combined with patent-protected market exclusivity, our product development programs with our partners now retain an even stronger position in the market."

OBJ has already been granted patent protection in the USA and Europe for its powered programmable array technology that currently underpins the Connect Beauty and Personalised Skincare initiatives.

About OBJ

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

Directors

Mr Glyn Denison
Mr Jeffrey Edwards
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
Fax: +61 8 9443 9960
www.obj.com.au
ABN: 72 056 482 636

12 October 2016

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilise diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward Looking Statements

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

OBJ Limited:	284 Oxford Street	Phone: +61 8 9443 3011
Mr Glyn Denison – Director	Leederville	Fax: +61 8 9443 9960
www.obj.com.au	Western Australia 6007	

Media/Investor relations:

Matthew Wright
matt@nwrcommunications.com.au
Phone: +61 451 896 420